2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, Fanikos J, Connors J, Siegal D, Barnes G, Martin K, Angiolillo D, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind M, Ruff C, Goldhaber S, Krumholz H, Mehran R, Cushman M, Eikelboom J, Lip G, Weitz J, Lopes R, Bikdeli B. When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 444-465. PMID: 38233019, DOI: 10.1016/j.jacc.2023.10.038.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsAtrial FibrillationHumansRandomized Controlled Trials as TopicThrombosisVenous ThromboembolismVenous ThrombosisVitamin KConceptsDirect oral anticoagulantsStandard of careRandomized controlled trialsOral anticoagulantsAtrial fibrillationCatheter-associated deep vein thrombosisCerebral venous sinus thrombosisControlled trialsVitamin K antagonistsThrombotic antiphospholipid syndromeEnd-stage renal diseaseLeft ventricular thrombusVenous thromboembolism treatmentVenous sinus thrombosisDeep vein thrombosisRheumatic heart diseaseReview of randomized controlled trialsEvidence-based reviewK antagonistsAntiphospholipid syndromeSinus thrombosisVentricular thrombusVein thrombosisThromboembolism treatmentVenous thrombosis
2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealmentClinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry
Bikdeli B, Caraballo C, Trujillo-Santos J, Galanaud JP, di Micco P, Rosa V, Cusidó GV, Schellong S, Mellado M, del Valle Morales M, Gavín-Sebastián O, Mazzolai L, Krumholz HM, Monreal M, Prandoni P, Brenner B, Farge-Bancel D, Barba R, Bertoletti L, Tzoran I, Reis A, Bosevski M, Bounameaux H, Malý R, Verhamme P, Caprini J, Adarraga M, Agudo de Blas P, Aibar J, Amado C, Arcelus J, Ballaz A, Barbagelata C, Barrón M, Barrón-Andrés B, Blanco-Molina Á, Beddar Chaib F, Botella E, Buño-Ramilo B, Castro J, Chasco L, Criado J, de Ancos C, de Miguel J, del Toro J, Demelo-Rodríguez P, Díaz-Brasero A, Díaz-Pedroche M, Díaz-Peromingo J, Díaz-Simón R, Domínguez I, Dubois-Silva Á, Escribano J, Espósito F, Farfán-Sedano A, Fernández-Capitán C, Fernández-Reyes J, Fidalgo Á, Font C, Francisco I, Gabara C, Galeano-Valle F, García M, García-Bragado F, García de Herreros M, García de la Garza R, García-Díaz C, Gil-Díaz A, Giménez-Suau M, Gómez-Cuervo C, Grau E, Guirado L, Gutiérrez J, Hernández-Blasco L, Jara-Palomares L, Jaras M, Jiménez D, Jiménez R, Jiménez-Alfaro C, Jou I, Joya M, Lainez-Justo S, Lalueza A, Latorre-Díez A, Lobo J, López-Jiménez L, López-Miguel P, López-Núñez J, López-Reyes R, López-Sáez J, Lorenzo A, Madridano O, Maestre A, Marchena P, Martín del Pozo M, Martín-Martos F, Martínez-Urbistondo D, Mella C, Mercado M, Muñoz-Blanco A, Nieto J, Núñez-Fernández M, Olid-Velilla M, Otalora S, Otero R, Paredes-Ruiz D, Parra P, Parra V, Pedrajas J, Peris M, Porras J, Portillo J, Ruiz-Artacho P, Ruiz-Giménez N, Ruiz-Ruiz J, Ruiz-Sada P, Salgueiro G, Sánchez-Martínez R, Sánchez-Muñoz-Torrero J, Sancho T, Soler S, Suárez-Rodríguez B, Suriñach J, Tolosa C, Torres M, Torres-Sánchez A, Uresandi F, Valero B, Valle R, Varona J, Vázquez-Friol C, Vela L, Vela J, Villalobos A, Villares P, Zamora C, Ay C, Nopp S, Pabinger I, Engelen M, Vanassche T, Yoo H, Hirmerova J, Accassat S, Ait Abdallah N, Bura-Riviere A, Catella J, Couturaud F, Crichi B, Debourdeau P, Espitia O, Falvo N, Grange C, Helfer H, Lacut K, Le Mao R, Mahé I, Morange P, Moustafa F, Poenou G, Sarlon-Bartoli G, Suchon P, Quere I, Nikandish R, Braester A, Kenet G, Basaglia M, Bilora F, Bortoluzzi C, Brandolin B, Ciammaichella M, Corgna C, de Angelis A, Imbalzano E, Mastroiacovo D, Merla S, Pesavento R, Pomero F, Siniscalchi C, Tufano A, Visonà A, Vo Hong N, Zalunardo B, Kigitovica D, Rusa E, Skride A, Fonseca S, Martins-Duarte F, Meireles J. Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. JAMA Cardiology 2022, 7: 857-865. PMID: 35830171, PMCID: PMC9280612, DOI: 10.1001/jamacardio.2022.1988.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesCOVID-19HumansMaleMiddle AgedPostthrombotic SyndromePulmonary EmbolismRecurrenceRegistriesRisk FactorsVenous ThromboembolismVenous ThrombosisConceptsDeep vein thrombosisDistal deep vein thrombosisProximal DVTLong-term outcomesPulmonary embolismVein thrombosisPostthrombotic syndromeCohort studyClinical presentationLower riskIsolated Distal Deep Vein ThrombosisProximal deep vein thrombosisEnfermedad TromboEmbólica (RIETE) registryLower comorbidity burdenUpper extremity DVTInternational cohort studyMultivariable adjusted analysesOptimal long-term managementRandomized clinical trialsAnalysis of patientsCOVID-19 infectionLong-term managementAsymptomatic DVTComorbidity burdenInfrapopliteal veinsEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsAtrial FibrillationDabigatranHumansRivaroxabanStrokeVenous ThromboembolismConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patientsSex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study
Bikdeli B, Piazza G, Jimenez D, Muriel A, Wang Y, Khairani CD, Rosovsky RP, Mehdipoor G, O'Donoghue ML, Spagnolo P, Dreyer RP, Bertoletti L, López-Jiménez L, Núñez MJ, Blanco-Molina Á, Bates SM, Gerhard-Herman M, Goldhaber SZ, Monreal M, Krumholz HM. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. Thrombosis Research 2022, 214: 122-131. PMID: 35537232, DOI: 10.1016/j.thromres.2022.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansMaleMedicarePharmaceutical PreparationsPulmonary EmbolismRegistriesRisk FactorsSex CharacteristicsUnited StatesVenous ThromboembolismConceptsRisk factorsElderly patientsUS Medicare feeInterventional therapyMedicare feeInternational registryService beneficiariesSex differencesNational US databasePrognostic prediction rulePulmonary embolism studyLarge international registryPrincipal discharge diagnosisSex-based disparitiesAssessment of outcomesPotential sex differencesSex-specific findingsPE presentationPulmonary embolismVenous thromboembolismTreatment patternsDischarge diagnosisAvailable therapiesDisease presentationTreatment-based differencesWomen's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment
Bikdeli B, Khairani CD, Barns BM, Rosovsky RP, Jimenez D, Monreal M, Sylvester KW, Middeldorp S, Bates SM, Krumholz HM, Goldhaber SZ, Hunt BJ, Piazza G. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials 2022, 115: 106714. PMID: 35202841, DOI: 10.1016/j.cct.2022.106714.Peer-Reviewed Original Research
2020
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
Bikdeli B, Talasaz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A, Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H, Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O, Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research 2020, 196: 382-394. PMID: 32992075, PMCID: PMC7513771, DOI: 10.1016/j.thromres.2020.09.027.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationKey safety endpointIll patientsProphylactic anticoagulationVenous thromboembolismMajor bleedingSafety endpointCOVID-19Bleeding Academic Research Consortium definitionAcademic Research Consortium definitionsTimes upper normal limitAcute arterial thrombosisExuberant immune responseMacrovascular thrombotic eventsPrespecified secondary analysisCritically Ill PatientsKey secondary endpointVentilator-free daysExtracorporeal membrane oxygenationUpper normal limitNon-inferiority marginReverse transcription-polymerase chain reactionCoronavirus disease 2019Transcription-polymerase chain reactionAtorvastatin 20Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project
Tafur A, Bikdeli B, Weinberg I, Jimenez D, Monreal A, Barba R, Mira E, Macrinici V, Krumholz HM, Hawkins M, Monreal M, . Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. Clinical And Applied Thrombosis/Hemostasis 2020, 26: 1076029620931200. PMID: 32936691, PMCID: PMC7498960, DOI: 10.1177/1076029620931200.Peer-Reviewed Original ResearchMeSH KeywordsData AggregationFemaleHumansMaleProspective StudiesRegistriesRisk AssessmentTreatment OutcomeVenous Thromboembolism
2019
Minimizing recurrent venous thromboembolism
Bikdeli B, Krumholz HM, Hines HH. Minimizing recurrent venous thromboembolism. The BMJ 2019, 366: l4686. PMID: 31345836, DOI: 10.1136/bmj.l4686.Peer-Reviewed Original Research
2018
Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE)
Bikdeli B, Jimenez D, Hawkins M, Ortíz S, Prandoni P, Brenner B, Decousus H, Masoudi FA, Trujillo-Santos J, Krumholz HM, Monreal M. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thrombosis And Haemostasis 2018, 118: 214-224. PMID: 29304541, PMCID: PMC5821113, DOI: 10.1160/th17-07-0511.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsCardiologyCause of DeathFemaleFollow-Up StudiesHemorrhageHumansInternational CooperationIschemiaPregnancyPregnancy Complications, CardiovascularProspective StudiesPuerperal DisordersPulmonary EmbolismRecurrenceRegistriesResearch DesignTreatment OutcomeVena Cava FiltersVenous ThromboembolismConceptsOutcomes of patientsVenous thromboembolismDeep vein thrombosisPulmonary embolismOngoing registryClinical trialsOutcomes of VTEPragmatic comparative effectiveness studyLong-term outcome dataUnstable pulmonary embolismPattern of presentationPatterns of carePrevalent vascular diseaseComparative effectiveness studiesHospital deathVein thrombosisVenous thrombosisPreventable causeComputerized registryVascular diseaseRIETEInclusion criteriaThrombotic conditionsOutcome dataPatients
2017
Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis
Bikdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, Spencer FA, Monreal M, Goldhaber SZ, Krumholz HM. Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis. Journal Of The American College Of Cardiology 2017, 70: 1587-1597. PMID: 28935036, PMCID: PMC8412839, DOI: 10.1016/j.jacc.2017.07.775.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisSubsequent pulmonary embolismInferior vena cava filterPulmonary embolismVena cava filtersIVC filtersCause mortalityOdds ratioCava filtersSystematic reviewSubsequent deep vein thrombosisInverse variance fixed-effect modelRisk of PECochrane Central RegisterQuality of evidenceFixed-effects modelCentral RegisterVein thrombosisControlled TrialsOverall mortalityObservational studyMAIN OUTCOMEPrimary analysisMeta-AnalysisMortality